Aldeyra Therapeutics Business Summary

Aldeyra Therapeutics, Inc. (ALDX) is a clinical-stage biotechnology company that generates revenue primarily through strategic licensing agreements and collaboration options, most notably an exclusive option agreement with AbbVie for its lead candidate, reproxalap. The company operates through two primary business segments: ophthalmic diseases, focusing on dry eye disease and allergic conjunctivitis, and systemic immune-mediated diseases, which leverage its proprietary reactive aldehyde species (RASP) modulator platform. As of February 23, 2026, the company is in a critical pre-commercial phase, awaiting a March 16, 2026, PDUFA action date for reproxalap following a major amendment to its New Drug Application. Aldeyra competes directly with established ophthalmology players such as Bausch + Lomb, AbbVie (Restasis), Ocular Therapeutix, and Eyepoint Pharmaceuticals, positioning itself as a specialized developer of first-in-class small-molecule modulators designed to treat inflammation upstream of traditional cytokine targets. The company is led by President and CEO Todd C. Brady, M.D., Ph.D., who has headed the firm since 2012 and previously served as a Principal at Domain Associates; he is supported by Michael Alfieri, who serves as Principal Financial Officer and Principal Accounting Officer via Danforth Global. The founding pedigree includes Ben Bronstein, M.D., who established the company's predecessor, Neuron Systems, and remains an influential figure in its clinical strategy. The leadership team is currently navigating a transition as Chief Development Officer Stephen G. Machatha, Ph.D., is slated to resign by March 31, 2026. Aldeyra’s board of directors features prominent industry veterans, including Neal Walker (CEO of Aclaris Therapeutics), Nancy Miller-Rich (formerly of Merck), and Chip Clark (formerly of Genocea Biosciences), while institutional backing is anchored by major investors such as Vanguard and BlackRock.